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Abstract
The whole-genome sequences of 24 isolates of Neisseria gonorrhoeae with elevated minimum 
inhibitory concentrations (MICs) to azithromycin (≥2.0 μg/mL) were analyzed against a modified 
sequence derived from the whole-genome sequence of N. gonorrhoeae FA1090 to determine, by 
signal ratio, the number of mutant copies of the 23S rRNA gene and the copy number effect on 
50S ribosome-mediated azithromycin resistance. Isolates that were predicted to contain four 
mutated copies were accurately identified compared with the results of direct sequencing. Fewer 
than four mutated copies gave less accurate results but were consistent with elevated MICs.
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1. Introduction
In 2012, European sexually transmitted diseases guidelines began recommending the 
administration of ceftriaxone and azithromycin for gonococcal infections [1,2]. The use of 
dual-drug regimens reflects fears of untreatable gonorrhoea [3] and is predicated on the 
hypothesis that simultaneous emergence of resistance to each of these antibiotics will be 
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infrequent and will be slowed by using them in combination [1]. However, strains resistant 
to azithromycin have been observed globally, with azithromycin minimum inhibitory 
concentrations (MICs) of ≥1.0 μg/mL associated with treatment failure [4,5]. The emergence 
of such strains highlights the need for tools to assist in the rapid identification of 
azithromycin-resistant isolates. Whole-genome sequencing (WGS) raises the possibility of 
developing molecular diagnostics to detect resistance and for use in ongoing surveillance 
and epidemiological monitoring of strain populations. Here we present an analysis of 23S 
rRNA-mediated resistance to azithromycin and compare the results from short-read WGS-
based bioinformatic analysis with nested PCR and sequencing of the individual 23S rRNA 
copies.
Several genetic pathways appear to confer resistance to azithromycin. Mutations in mtrR, a 
transcriptional repressor that alters expression of the mtrCDE efflux pump operon, confer 
resistance to erythromycin and low-level resistance to azithromycin (0.5 μg/mL) [6,7]. These 
mutations include deletions and insertions within the inverted repeat in the mtrR promoter as 
well as point mutations within the structural gene [6]. In a set of clinical isolates from an 
outbreak in Kansas City (Missouri), a Correia element inserted into the mtrCDE promoter 
region between the transcriptional initiation site and the start codon of mtrC resulted in 
azithromycin MICs of ≥2.0 μg/mL. An additional insertion mutation in the 5′ coding region 
of the mtrR structural gene in a related cluster of strains increased the MIC to ≥4.0 μg/mL 
[8]. Mutational modifications in the 50S ribosomal target of azithromycin confer 
azithromycin resistance substantially greater than the resistance conferred by mutations in 
the mtr-mediated efflux system. The ribosomal mutations consist of characteristic mutations 
at one of two sites in the 23S rRNA, i.e. C2599T (Neisseria gonorrhoeae numbering) and 
A2059G (N. gonorrhoeae numbering)] [9–11]. Neisseria gonorrhoeae usually possesses four 
copies of the 23S rRNA per genome equivalent, and the greatest resistance has been reported 
for those isolates with all four copies as mutant alleles. In those instances where all four 
copies are mutant alleles C2599T confers moderate resistance (8–16 μg/mL), and the 
A2059G mutation confers high-level resistance (≥64 16 μg/mL) [10].
2. Materials and methods
2.1. Isolate selection and bioinformatic analysis
The ability of bioinformatic analysis of WGS data to accurately predict the number of 
mutant allele 23S rRNA copies in the genomes of N. gonorrhoeae isolates was investigated. 
Using a collection of gonococcal isolates with azithromycin MICs of ≥2.0 μg/mL taken from 
a previous larger study of 246 isolates for which full genome sequences and MIC data are 
available [12], the number of predicted 23S rRNA copies with the C2599T substitution was 
correlated with the azithromycin MIC. No substitutions at the 2059 site were observed in 
this collection. Isolates were selected, genomic DNA was extracted and sequenced, and the 
data were analyzed as described elsewhere [12]. The readings were mapped by SMALT [12] 
against a version of the N. gonorrhoeae FA1090 genome sequence (GenBank accession no. 
AE004969) from which three of the four 23S rRNA copies (those starting at nucleotides 116 
247, 1 258 350 and 1 649 926) were deleted in silico. The ratio of C to T nucleotide calls 
from reads covering the 2599 site was determined by SAMtools [13] to establish the 
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predicted number of mutant allele copies present in a particular isolate. Based on the 
expectation of four genomic 23S rRNA copies in each isolate, the ratios were rounded to the 
nearest quartile.
2.2. Direct sequencing of 23S rRNA gene copies
Subsequently, the number of mutant allele copies present in each of the isolates was 
determined by directly sequencing each 23S rRNA copy in each isolate using the methods 
and primers described elsewhere [9]. Briefly, the copies were amplified separately using a 
common 23S rRNA primer with a unique external counter-primer adjacent to the desired 
copy. Each of these amplified fragments was then nested with internal rRNA primers that 
covered the region to be sequenced and included sites at which base substitutions 
responsible for azithromycin resistance are located.
3. Results and discussion
A total of 24 isolates with azithromycin MICs ≥ 2.0 μg/mL as determined by agar dilution 
were analyzed. Two isolates from the same collection with MICs of 1.0 μg/mL were 
included as sensitive controls and contained no mutations in any of the rRNA copies. The 
genomic sequencing results giving the estimated number of mutant alleles for each of the 
isolates were compared with the results obtained by directly sequencing each independent 
23S rRNA copy (Table 1). Overall, isolates shown to have at least two mutant 23S rRNA 
copies by direct sequencing and an azithromycin MIC ≥ 2.0 μg/mL were correctly identified 
by WGS, indicating successful genotypic prediction of ribosome-mediated phenotypic 
resistance.
We further assessed the prediction of mutant copy number by WGS. Allowing for the 
omission of the single isolate that contained only three intact copies of the 23S rRNA (Table 
1), the data showed that 18/19 (95%) of the isolates predicted by the WGS-based method to 
contain all copies as mutant alleles were confirmed by direct PCR and sequencing; only a 
single isolate was erroneously called by the WGS method. For estimated mutant copies less 
than four, the results were less accurate. Four isolates that were estimated by WGS 
methodology to contain two of four or three of four mutant copies agreed with the results 
from direct sequencing in only a single instance (Table 2). However, the extent of 
disagreement amounted to only a single copy for each discrepancy, and in no case of an 
azithromycin MIC ≥ 2.0 μg/mL was the WGS-based result less than two variant alleles. Of 
note, the use of a variant ratio dependent on the expectation of four genomic 23S rRNA 
copies does not allow for differences that may result from such issues as the atypical 23S 
rRNA copy numbers noted above. Within the relatively small collection of isolates analyzed 
here, one of them was found to possess three functional intact copies of the 23S rRNA, 
while the fourth copy appeared to have sustained a significant internal deletion that led to 
failed attempts at amplification. In addition, potential sources of error include polyploidy 
with 23S rRNA variation in genomes and undetected mixed populations.
The fraction of mutated 23S rRNA copies correlated with the MICs obtained. Those isolates 
with all 23S rRNA copies mutated gave azithromycin MICs (8.0 μg/mL and 16.0 μg/mL) 
higher than those with a fraction of the copies mutated, with the exception of a single isolate 
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(GCGC018) that despite possessing only three of four mutated of 23S rRNA gene copies 
exhibited an azithromycin MIC of 16.0 μg/mL. It is tempting to speculate that this isolate 
possesses at least one additional mutation elsewhere in the genome that contributes to this 
unexpectedly high MIC. The relatively low MICs obtained for those isolates that possessed 
at least one wild-type sensitive copy of the 23S rRNA suggested that the presence of even a 
single sensitive allele influenced the MIC more than the absolute number of resistant alleles. 
Moreover, the absence of isolates with only a single C2599T allele suggests that a single 
mutant 23S rRNA copy alone does not confer an MIC above the 2.0 μg/mL threshold used to 
designate isolates with reduced susceptibility.
4. Conclusion
These findings show that a bioinformatic analysis of short-read WGS data correctly 
predicted an association between at least two copies of the C2599T 23S rRNA allele and 
reduced susceptibility to azithromycin. While the approach does not perform perfectly when 
judged against the results obtained by sequencing the nested PCR products from the 
individual alleles, it none the less accurately predicts an azithromycin-resistant genotype and 
broadly indicates an associated phenotype. In addition, analysis of WGS data may indicate 
additional mechanisms of azithromycin resistance, as for GCGS018, which exhibits an 
unusually high azithromycin MIC of 16.0 μg/mL for an isolate with three mutant 23S rRNA 
copies. With the possible exception of GCGS018, no other isolates indicated mechanisms of 
azithromycin resistance other than mutations in the 23S rRNA, nor were any of the other 
known mechanisms for azithromycin resistance at 2.0 μg/mL found. Finally, these findings 
document the first observation of a gonococcal isolate with three, rather than four, genomic 
copies of the 23S rRNA, emphasizing the plasticity of the gonococcal genome. The genome 
reads are available in the SRA, NCBI BioProject PRJEB2999.
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Table 1
Estimated and actual 23S rRNA allele distributions of strains with azithromycin minimum inhibitory 
concentrations (MICs) of ≥2.0 μg/mL
Strain # Genomic estimated 23S rRNA allele distribution Actual sequence determined 23S rRNA allele 
distribution
MIC (μg/mL)
GCGS039 ND 0/4 1.0a
GCGS196 ND 0/4 1.0a
GCGS018 4/4 3/4 16.0
GCGS038 4/4 4/4 8.0
GCGS096 4/4 4/4 16.0
GCGS098 4/4 4/4 16.0
GCGS102 3/4 2/4 2.0
GCGS104 2/4 3/4 2.0
GCGS106 4/4 4/4 8.0
GCGS110 4/4 4/4 16.0
GCGS118 3/4 4/4 8.0
GCGS120 4/4 4/4 8.0
GCGS128 4/4 4/4 8.0
GCGS136 4/4 4/4 8.0
GCGS142 4/4 3/3b 8.0
GCGS156 4/4 4/4 16.0
GCGS174 4/4 4/4 16.0
GCGS176 4/4 4/4 16.0
GCGS198 4/4 4/4 16.0
GCGS202 4/4 4/4 8.0
GCGS204 4/4 4/4 8.0
GCGS218 4/4 4/4 16.0
GCGS224 4/4 4/4 8.0
GCGS226 4/4 4/4 16.0
GCGS228 2/4 2/4 2.0
GCGS230 4/4 4/4 8.0
aSensitive controls.
bAllele 4 did not amplify.
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Table 2
Distribution of mutant rRNA alleles.
Mutant/total allelic distribution No. of estimated calls No. of estimated calls confirmed by 
sequencing
Azithromycin MIC (μg/mL)
4/4 19a 18 8 (n = 9), 16 (n = 9)
3/4 2 0 16 (n = 1), 2 (n = 1)
2/4 2 1 2 (n = 2)
MIC, minimum inhibitory concentration.
aGCGS142 (MIC = 8.0 μg/mL) was omitted from this analysis since one allele could not be amplified or sequenced
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